(Circulation. 2000;102:2880.)
© 2000 American Heart Association, Inc.
Basic Science Reports |
From the Department of Cardiology (W.B., N.V.P., H.G., S.J.) and Center for Transgene Technology and Gene Therapy (P.P., Z.N., R.G., D.C., S.J.), Flanders Interuniversity Institute of Biotechnology, University of Leuven, Belgium; IntroGene (P.P.), Leuven, Belgium; University of New Mexico Health and Sciences Center (R.L.), Albuquerque; and Cardiovascular Research Center (K.D.B.), Massachusetts General Hospital, Harvard Medical School, Boston, Mass.
Correspondence to Stefan Janssens, MD, PhD, Center for Transgene Technology and Gene Therapy, 49 Herestraat, B-3000 Leuven, Belgium. E-mail stefan.janssens{at}med.kuleuven.ac.be
BackgroundNitric oxide (NO) is a potent vasodilator with an important role in the regulation of pulmonary vascular tone. The effects of NO synthase (NOS) gene transfer on pulmonary vascular remodeling associated with hypoxic pulmonary hypertension are unknown.
Methods and ResultsWe aerosolized 3x109 pfu of an adenoviral vector containing inducible NOS gene (AdNOS2), constitutive NOS3 gene (AdNOS3), or no transgene (AdRR5) into rat lungs. Exhaled NO levels, monitored with chemiluminescence, were higher in AdNOS2-infected rats than in AdNOS3- and AdRR5-infected rats (at 3 days, 33±6 ppb, n=9, versus 17±4, n=9, and 6±2 ppb, n=3, P<0.05 for both). Exposure to FIO2 0.10 for 7 days increased pulmonary artery pressure from 19±4 mm Hg (baseline) to 27±1 and 26±2 mm Hg in AdNOS3- and AdRR5-infected rats, respectively, but only to 21±1 mm Hg in AdNOS2-infected animals (P<0.05). After 7 days of hypoxia, total pulmonary resistance in AdRR5- and AdNOS3-infected rats was significantly higher than in AdNOS2-infected animals (0.41±0.05 and 0.39±0.07 versus 0.35±0.03 mm Hg · mL-1 · min-1, respectively, P<0.05). Right ventricular hypertrophy was reduced in AdNOS2-infected rats [right ventricular/(left ventricular+septal) weight, 0.19±0.10 versus 0.28±0.10 and 0.32±0.10 in AdRR5- and AdNOS3-infected rats, respectively, P<0.05]. The percentage of muscularized precapillary pulmonary resistance vessels was also significantly decreased (18±4% versus 25±8% and 30±5% in AdRR5- and AdNOS3-infected rats, P<0.05).
ConclusionsAerosol NOS2 gene transfer increases pulmonary NO production and significantly reduces hypoxic pulmonary hypertension and pulmonary vascular remodeling. Aerosol NOS2 gene transfer may be a promising strategy to target pulmonary vascular disorders.
Key Words: nitric oxide synthase hypertension, pulmonary genes vasculature remodeling
This article has been cited by other articles:
![]() |
P. Pokreisz, G. Marsboom, and S. Janssens Pressure overload-induced right ventricular dysfunction and remodelling in experimental pulmonary hypertension: the right heart revisited Eur. Heart J. Suppl., December 1, 2007; 9(suppl_H): H75 - H84. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. P. Coggins and K. D. Bloch Nitric Oxide in the Pulmonary Vasculature Arterioscler Thromb Vasc Biol, September 1, 2007; 27(9): 1877 - 1885. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Liu, H. Liu, G. Visner, and B. S. Fletcher Sleeping Beauty-mediated eNOS gene therapy attenuates monocrotaline-induced pulmonary hypertension in rats FASEB J, December 1, 2006; 20(14): 2594 - 2596. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. P. Stanley, L. G. Chicoine, T. L. Young, K. M. Reber, C. R. Lyons, Y. Liu, and L. D. Nelin Gene transfer with inducible nitric oxide synthase decreases production of urea by arginase in pulmonary arterial endothelial cells Am J Physiol Lung Cell Mol Physiol, February 1, 2006; 290(2): L298 - L306. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. D. Hoit, N. D. Dalton, S. C. Erzurum, D. Laskowski, K. P. Strohl, and C. M. Beall Nitric oxide and cardiopulmonary hemodynamics in Tibetan highlanders J Appl Physiol, November 1, 2005; 99(5): 1796 - 1801. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. G. Chicoine, E. Tzeng, R. Bryan, S. Saenz, M. L. Paffett, J. Jones, C. R. Lyons, T. C. Resta, L. D. Nelin, and B. R. Walker Intratracheal adenoviral-mediated delivery of iNOS decreases pulmonary vasoconstrictor responses in rats J Appl Physiol, November 1, 2004; 97(5): 1814 - 1822. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. L. M. Ricciardolo, P. J. Sterk, B. Gaston, and G. Folkerts Nitric Oxide in Health and Disease of the Respiratory System Physiol Rev, July 1, 2004; 84(3): 731 - 765. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Y.H. Chan, L.-L. Wang, Y.-M. Chao, and S. H.H. Chan Downregulation of Basal iNOS at the Rostral Ventrolateral Medulla Is Innate in SHR Hypertension, March 1, 2003; 41(3): 563 - 570. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. C. Champion, T. J. Bivalacqua, S. S. Greenberg, T. D. Giles, A. L. Hyman, and P. J. Kadowitz Adenoviral gene transfer of endothelial nitric-oxide synthase (eNOS) partially restores normal pulmonary arterial pressure in eNOS-deficient mice PNAS, October 1, 2002; 99(20): 13248 - 13253. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Ono, Y. Sawa, K. Matsumoto, T. Nakamura, Y. Kaneda, and H. Matsuda In Vivo Gene Transfection With Hepatocyte Growth Factor via the Pulmonary Artery Induces Angiogenesis in the Rat Lung Circulation, September 24, 2002; 106(12_suppl_1): I-264 - I-269. [Abstract] [Full Text] [PDF] |
||||
![]() |
W Budts, N Van Pelt, H Gillyns, M Gewillig, F Van de Werf, and S Janssens Residual pulmonary vasoreactivity to inhaled nitric oxide in patients with severe obstructive pulmonary hypertension and Eisenmenger syndrome Heart, November 1, 2001; 86(5): 553 - 558. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Khurana, J. F. Martin, and I. Zachary Gene Therapy for Cardiovascular Disease: A Case for Cautious Optimism Hypertension, November 1, 2001; 38(5): 1210 - 1216. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Vermeersch, Z. Nong, E. Stabile, O. Varenne, H. Gillijns, M. Pellens, N. Van Pelt, M. Hoylaerts, I. De Scheerder, D. Collen, et al. L-Arginine Administration Reduces Neointima Formation After Stent Injury in Rats by a Nitric Oxide-Mediated Mechanism Arterioscler Thromb Vasc Biol, October 1, 2001; 21(10): 1604 - 1609. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. A. KHARITONOV and P. J. BARNES Exhaled Markers of Pulmonary Disease Am. J. Respir. Crit. Care Med., June 1, 2001; 163(7): 1693 - 1722. [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2000 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |